Fabrice Andre, MD, PhD, on Breast Cancer: Interim Analysis From DESTINY-Breast07
2024 ASCO Annual Meeting
Fabrice Andre, MD, PhD, of Gustave Roussy and the Université Paris-Saclay, discusses a dose-expansion interim analysis of trastuzumab deruxtecan (T-DXd) monotherapy and T-DXd plus pertuzumab in patients with previously untreated HER2-positive metastatic breast cancer (Abstract 1009).
Transcript
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
HER2 overexpression breast cancer represents around 20% of patients with metastatic breast cancer. The outcome in recent trials is around 50 to 60 months median overall survival with the first-line therapy being Taxane plus Trastuzumab plus Pertuzumab, and this combination provides around 18 months progression-free survival. In this context, there is a need to improve the outcome of these patients.
Trastuzumab Deruxtecan is a new drug, it is an antibody-drug conjugate that targets HER2. This drug has shown efficacy in patients who present with HER2 overexpression metastatic breast cancer, previously treated with Taxane Pertuzumab Trastuzumab. In this context, the question is whether giving Trastuzumab Deruxtecan in the first-line setting could improve the outcome of patients.
Before moving to the Phase IV / Phase III, it was necessary to run the Phase I / Phase II to explore the safety and preliminary signal of efficacy. In DESTINY-Breast07 Phase I / Phase II, 75 patients were included in the first-line setting to receive Trastuzumab Deruxtecan. 50 patients were included again in the first-line setting to receive Trastuzumab Deruxtecan plus Pertuzumab.
What are the results? The response rate was 76% in patients who received Trastuzumab Deruxtecan single agent, and was 84% in the group of patients who received Trastuzumab Deruxtecan plus Pertuzumab. In terms of progression-free survival, it's too early to conclude. Nevertheless, more than 80% of the patients, whether they were treated with Trastuzumab Deruxtecan or T-DXd plus Pertuzumab, more than 80% of the patients had a progression-free survival more than 12 months. Meaning that the disease is controlled for the vast majority of patients for more than 12 months. Then in terms of subgroup, there was no difference of efficacy according to the expression of hormone receptor or whether the disease was recurrent after adjuvant therapy or de novo.
In terms of safety, around 10% of patients presented with ILD, which is lung toxicity. Nevertheless, no toxic death was observed. One toxicity that was moderate, but that was increased with Pertuzumab, was diarrhea, but still the number and the percentage are very small.
So what can we say about this study? It's a Phase I / Phase II study that tells us that in the first-line setting, T-DXd or T-DXd plus Pertuzumab, provides encouraging preliminary signal of efficacy, and that was the rationale to start a Phase III trial testing this new drug in the first-line setting as compared to the standard of care, and hopefully will improve the outcome of the patients.
The ASCO Post Staff
Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).
The ASCO Post Staff
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, and Thomas Powles, MD, PhD, of Barts Cancer Institute and the University of London, discuss phase III findings from two studies: the first, investigating enfortumab vedotin-ejfv and pembrolizumab vs platinum-based chemotherapy in previously untreated patients with locally advanced or metastatic urothelial cancer; and the second, looking at nivolumab plus gemcitabine and cisplatin vs gemcitabine and cisplatin alone in patients with lymph node–only metastatic disease enrolled in the CheckMate 901 trial (Abstracts 4581 and 4565).
The ASCO Post Staff
Peter Riedell, MD, of The University of Chicago, discusses phase III findings on the regimen of brentuximab vedotin in combination with lenalidomide and rituximab for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This therapy demonstrated a survival advantage in the third-line setting, but as this is an interim analysis, questions remain regarding long-term safety and duration of response, according to Dr. Riedell (Abstract LBA7005).
The ASCO Post Staff
Efrat Dotan, MD, of Fox Chase Cancer Center, discusses results from the phase II EA2186 trial, the first prospective study aiming to define the optimal treatment approach for vulnerable older adults with newly diagnosed metastatic pancreatic cancer (Abstract 4003).
The ASCO Post Staff
Clifford A. Hudis, MD, CEO of the American Society of Clinical Oncology (ASCO), and Karen E. Knudsen, MBA, CEO of the American Cancer Society, discuss a newly launched collaboration between the organizations to make it simpler for patients to find authoritative cancer information online. The effort creates one of the largest and most comprehensive online resources for credible cancer information, available for free to the public on cancer.org.